Sung Kyun Biotech Co., Ltd.
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
0
Ending by 2030
May 2037
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Mar 5, 2027The maintenance fee for Antibody Composition Specifically Recognizing an Immunogenic Fragment Peptide of EN2 Protein (US 11,746,146) comes due Mar 5, 2027. Unpaid by Sep 7, 2027, it lapses early.
- 1 fee due May 28, 2027The maintenance fee for Antibody Composition Specifically Recognizing an Immunogenic Fragment Peptide of EN2 Protein (US 11,827,696) comes due May 28, 2027. Unpaid by Nov 29, 2027, it lapses early.
- 1 fee due Jun 3, 2027The maintenance fee for Compound promoting osteoblast differentiation and inhibiting adipocyte differentiation, preparation method thereof and application thereof (US 10,494,356) comes due Jun 3, 2027. Unpaid by Dec 3, 2027, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Showing 1 to 5 of 5
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 10,494,356 | Compound promoting osteoblast differentiation and inhibiting adipocyte differentiation, preparation method thereof and application thereof In force · USPTO record | In force | USPTO record | |
| US 11,746,146 | Antibody Composition Specifically Recognizing an Immunogenic Fragment Peptide of EN2 Protein In force · High confidence | In force | High confidence | |
| US 11,827,696 | Antibody Composition Specifically Recognizing an Immunogenic Fragment Peptide of EN2 Protein In force · High confidence | In force | High confidence | |
| US 11,058,740 | Composition for preventing, alleviating or treating stress diseases, containing Platycodon grandiflorum extract as active ingredient In force · USPTO record | In force | USPTO record | |
| US 11,498,945 | Immunogenic Fragment Peptide of EN2 Protein or Antibody Composition Specifically Recognizing Same In force · High confidence | In force | High confidence |
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
1 no status recorded